The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
Open accessAbstract
BACKGROUND: Osteoprotegerin (OPG) is a decoy receptor for OPG ligand (OPGL), or receptor activator of NF-kappaB ligand (RANKL). RANKL/RANK interaction is important in terminal differentiation and activation of osteoclasts. In binding to RANKL, OPG blocks differentiation and activation of osteoclasts. AMGN-0007 is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease. METHODS: A randomized, double-blind, double-dummy, active-controlled, single-dose, dose escalation study was conducted to determine the safety and effect on bone resorption of AMGN-0007 in patients with multiple myeloma (n = 28) or breast carcinoma (n = 26) with radiologically confirmed lytic bone lesions. Patients were randomized (3:1 ratio) to receive a single dose of either AMGN-0007 (subcutaneously [SC]) or pamidronate (90 mg intravenously) and were followed for 56 days. Medications or other diseases affecting bone metabolism and chemotherapy within 28 days of dosing were exclusion criteria. Biologic activity of AMGN-0007 was assessed by measurement of the surrogate marker of bone resorption, urinary N-telopeptide of collagen (NTX). RESULTS: AMGN-0007 caused a rapid, sustained, dose-dependent decrease in NTX/creatinine levels, which was at least comparable to the profile observed with pamidronate. Four serious adverse events were reported, three in breast carcinoma patients: a fracture in the left femur (pamidronate, considered unrelated), extreme fatigue (0.3 mg/kg AMGN-0007, considered unrelated), and congestive heart failure (1.0 mg/kg AMGN-0007, considered by the investigator to be probably related to doxorubicin and radiation therapy); one event occurred in a multiple myeloma patient: Herpes zoster (pamidronate, considered unrelated). Two multiple myeloma patients (1.0 mg/kg AMGN-0007) had albumin-adjusted serum calcium levels of 1.9 mmol/L on Day 8 but without clinical symptoms. CONCLUSIONS: A single SC dose of AMGN-0007 suppressed bone resorption as indicated by a rapid, sustained, and profound decrease of urinary NTX/creatinine in multiple myeloma and breast carcinoma patients. Changes were comparable to those with pamidronate. AMGN-0007 was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A dose-dependent reduction in uNTX occurred within 1 d of dosing with OPG-Fc, and uNTX reached a nadir of approximately Ϫ60 and Ϫ84% in the MM and breast cancer strata, respectively, at the higher doses (1.0 and 3.0 mg/kg).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [23]
In the citing paper
“Suppression of bone resorption was maintained throughout the duration of the study (56 d).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [23]
In the citing paper
“The pharmacodynamic profile of OPG-Fc was generally similar to that observed with the open-label active control, pamidronate.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A. K., Porter, L. L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A. M., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,075
Self-citationHortobágyi, G. N., Theriault, R. L., Porter, L. L., Blayney, D. W., Lipton, A., Sinoff, C., Wheeler, H. T., Simeone, J. F., Seaman, J. J., Knight, R., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,024
Self-citationIsolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.
Tsuda, E., Goto, M., Mochizuki, S.-I., Yano, K., Kobayashi, F., Morinaga, T., & Higashio, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6603 · Cited by 787
Berenson, J. R., Lichtenstein, A. K., Porter, L., Dimopoulos, M. A., Bordoni, R. E., George, S., Lipton, A., Keller, A. M., Ballester, O., Kovacs, M. J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 645
Self-citationHortobágyi, G. N., Theriault, R. L., Lipton, A., Porter, L., Blayney, D. W., Sinoff, C., Wheeler, H. T., Simeone, J. F., Seaman, J. J., Knight, R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2038 · Cited by 630
Self-citationTheriault, R. L., Lipton, A., Hortobágyi, G. N., Leff, R., Glück, S., Stewart, J. F., Costello, S., Kennedy, I., Simeone, J. F., Seaman, J. J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.846 · Cited by 603
Self-citationHonoré, P., Luger, N. M., Sabino, M. A. C., Schwei, M. J., Rogers, S. D., Mach, D. B., O'keefe, P. F., Ramnaraine, M. L. R., Clohisy, D. R., & Mantyh, P. W. (2000) · Nature Medicine · doi:10.1038/74999 · Cited by 497
Flagged first, then by citations
Research works printed but not linked: 2
- Caparelli, 2000, Cancer Res., 60, 783
- Morony, 2001, Cancer Res., 61, 4432
Cited by
Sorted by citations
Items 201–300 of 384
Molecular mechanisms, current management and next generation therapy in myeloma bone disease
Heusschen, R., Muller, J., Duray, E., Withofs, N., Bolomsky, A., Baron, F., Beguin, Y. P., Menu, E., Ludwig, H., & Caers, J. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1323272 · Cited by 22
A missense mutation sheds light on a novel structure–function relationship of RANKL
Qiu, H., Qin, A., Cheng, T., Chim, S. M., Smithers, L., Chen, K., Song, D., Liu, Q., Zhao, J., Wang, C., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30045 · Cited by 23
Cody, J. J., Rivera, Á. A., Lyons, G. R., Yang, S. W., Wang, M., Sarver, D. B., Wang, D., Selander, K. S., Kuo, H.-C., Meleth, S., et al. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.47 · Cited by 22
OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer
Sänger, N., Ruckhäberle, E., Bianchini, G., Heinrich, T. M., Milde‐Langosch, K., Müller, V., Rody, A., Solomayer, E. F., Fehm, T. N., Holtrich, U., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.04.003 · Cited by 20
Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer
Lee, R. J., Saylor, P. J., & Smith, M. R. (2010) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2010.n.005 · Cited by 20
Microsphere controlled drug delivery for local control of tooth movement
Sydorak, I., Dang, M., Baxter, S. J., Halcomb, M. J., Ma, P. X., Kapila, S., & Hatch, N. E. (2018) · European Journal of Orthodontics · doi:10.1093/ejo/cjy017 · Cited by 20
Multiple Myeloma: Most Common End-Organ Damage and Management
Hussein, M. A. (2007) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2007.0017 · Cited by 20
Lorz, C. (2009) · Frontiers in bioscience · doi:10.2741/3485 · Cited by 20
Medical management of skeletal metastasis
Yu, M. K., & Buys, S. S. (2004) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2004.04.015 · Cited by 20
Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells
Ségaliny, A. I., Cheng, J. L., Farhoodi, H. P., Toledano, M., Yu, C. C., Tierra, B. A., Hildebrand, L., Liu, L., Liao, M. J., Cho, J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.047 · Cited by 19
Usefulness of Bone Formation Markers in Breast Cancer
Palma, M. A., & Body, J. (2005) · The International Journal of Biological Markers · doi:10.1177/172460080502000302 · Cited by 19
Self-citationGranchi, D., Garaventa, A., Amato, I., Paolucci, P., & Baldini, N. (2006) · International Journal of Cancer · doi:10.1002/ijc.21783 · Cited by 18
Vij, R., Horvath, N., Spencer, A. G., Taylor, K., Vadhan‐Raj, S., Smith, J. W. G., Qian, Y., & Jun, S. (2007) · Blood · doi:10.1182/blood.v110.11.3604.3604 · Cited by 19
Kraj, M. A., Owczarska, K., Sokołowska, U., Centkowski, P., Pogłód, R., & Kruk, B. (2005) · PubMed · Cited by 19
Yang, K., Li, S., Wang, T., Yan, X., Qian, H., Ning, R., Xu, X. Y., Yao, W., Zhang, X., Yang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00081 · Cited by 17
Emerging therapies in metastatic bone pain
Coluzzi, F., Mandatori, I., & Mattia, C. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.576668 · Cited by 18
Bone Disease in Multiple Myeloma
Hjertner, Ø., Standal, T., Børset, M., Sundan, A., & Waage, A. (2006) · Medical Oncology · doi:10.1385/mo:23:4:431 · Cited by 18
Télétchéa, S., Stresing, V., Hervouet, S., Baud’huin, M., Heymann, M., Bertho, G., Charrier, C., Ando, K., & Heymann, D. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2170 · Cited by 18
Kamiya, N., Suzuki, H., Endo, T., Takano, M., Yano, M., Naoi, M., Kawamura, K., Imamoto, T., Takanami, M., & Ichikawa, T. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0193-7 · Cited by 17
Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches.
Papadopoulou, E., Batzios, S. P., Dimitriadou, M., Perifanis, V., & Garipidou, V. (2010) · PubMed Central · Cited by 15
Bone signaling pathways and treatment of osteoporosis
Gogakos, A. I., Cheung, M., Bassett, J. H. D., & Williams, G. R. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.38 · Cited by 17
Kaklamanos, E. G., Makrygiannakis, M. A., & Athanasiou, A. E. (2020) · Orthodontics and Craniofacial Research · doi:10.1111/ocr.12411 · Cited by 16
Osteoprotegerin as a potential therapy for osteoporosis
Hamdy, N. A. T. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-006-0026-2 · Cited by 16
Sims, T. L., Hamner, J. B., Bush, R. A., Fischer, P. E., Kim, S. U., Aboody, K. S., McCarville, M. B., Danks, M. K., & Davidoff, A. M. (2009) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2008.10.041 · Cited by 16
Animal Models of Multiple Myeloma Bone Disease
Mehdi, S. H., Nafees, S., Mehdi, S. J., Morris, C., Mashouri, L., & Yoon, D. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.640954 · Cited by 17
Osteoprotegerin (OPG) pathways in bone diseases and its application in therapeutic perspectives
Jayash, S. N., Al-Namnam, N. M., & Shaghayegh, G. (2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac102.193200 · Cited by 15
Gralow, J. R. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.s.005 · Cited by 15
Higgs, J. T., Jarboe, J. S., Lee, J. H., Chanda, D., Lee, C. M., Deivanayagam, C. C. S., & Ponnazhagan, S. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0492 · Cited by 16
Modification of the RANKL-RANK-binding site for the immunotherapeutic treatment of osteoporosis
Ko, Y., Lee, G., Kim, B., Park, M., Jang, Y., & Lim, W. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05200-6 · Cited by 14
In vitroevaluation of osteoprotegerin in chitosan for potential bone defect applications
Jayash, S. N., Hashim, N. M., Misran, M., & Baharuddin, N. A. (2016) · PeerJ · doi:10.7717/peerj.2229 · Cited by 14
Treatment of multiple myeloma bone disease: experimental and clinical data
Papamerkouriou, Y. M., Kenanidis, E. I., Gamie, Z., Papavasiliou, K., Kostakos, T. A., Potoupnis, M. E., Sarris, I. K., Tsiridis, E. E., & Kyrkos, J. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.978853 · Cited by 15
Birgisson, H., Tsimogiannis, K. E., Freyhult, E., & Kamali‐Moghaddam, M. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.05.012 · Cited by 13
Local application of osteoprotegerin-chitosan gel in critical-sized defects in a rabbit model
Jayash, S. N., Hashim, N. M., Misran, M., & Baharuddin, N. A. (2017) · PeerJ · doi:10.7717/peerj.3513 · Cited by 13
Novel RANKL DE ‐loop mutants antagonize RANK ‐mediated osteoclastogenesis
Wang, Y., van Assen, A. H. G., Reis, C. R., Setroikromo, R., van Merkerk, R., Boersma, Y. L., Cool, R. H., & Quax, W. J. (2017) · FEBS Journal · doi:10.1111/febs.14142 · Cited by 12
Genes, molecules and patients—Emerging topics to guide clinical pain research
Sikandar, S., Patel, R., Patel, S., Sikander, S., Bennett, D., & Dickenson, A. H. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.069 · Cited by 12
New Strategies for the Treatment of Metastatic Bone Disease
Pearse, R. N. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.s.010 · Cited by 12
Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani, N., Colla, S., & Rizzoli, V. (2004) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · Cited by 12
Denosumab: A Promising Drug for the Prevention and Treatment of Osteoporosis
Lewiecki, E. M. (2006) · Women s Health · doi:10.2217/17455057.2.4.517 · Cited by 12
Osteoprotegerin as a potential therapy for osteoporosis
Hamdy, N. A. T. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-996-0014-5 · Cited by 15
Biochemical markers of bone metastasis
Lyubimova, N. V., & Kushlinskiy, N. E. (2015) · Advances in molecular oncology · doi:10.17650/2313-805x.2015.2.1.061-075 · Cited by 11
Genetic factors influencing the risk of multiple myeloma bone disease
Johnson, D. C., Weinhold, N., Mitchell, J. S., Chen, B., Stephens, O., Försti, A., Nickel, J., Kaiser, M., Gregory, W. M., Cairns, D. A., et al. (2015) · Leukemia · doi:10.1038/leu.2015.342 · Cited by 11
Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease
Salim, S. A., Nair, L. R., Thomas, L., Garla, V. V., Palabindala, V., Agarwal, M., & Fülöp, T. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.09.008 · Cited by 11
Elevated Microdamage Spatially Correlates with Stress in Metastatic Vertebrae
Atkins, A., Burke, M., Samiezadeh, S., Akens, M. K., Hardisty, M., & Whyne, C. M. (2019) · Annals of Biomedical Engineering · doi:10.1007/s10439-018-02188-8 · Cited by 11
Kopper, L. (2012) · Pathology & Oncology Research · doi:10.1007/s12253-012-9538-4 · Cited by 14
Dawson, S., & Lawrie, A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.017 · Cited by 11
Labropoulou, V., Theocharis, A. D., Symeonidis, A. S., Skandalis, S. S., Karamanos, N. K., & Kalofonos, H. P. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795471275 · Cited by 10
Metastatic bone cancer pain: Etiology and treatment options
O'Toole, G. C., & Boland, P. J. (2006) · Current Pain and Headache Reports · doi:10.1007/s11916-006-0034-y · Cited by 10
Lipton, A. (2009) · Breast Diseases A Year Book Quarterly · doi:10.1016/s1043-321x(09)79300-2 · Cited by 10
Self-citationZojer, N., Brenner, K., Beke, D., Kudlacek, S., Hawa, G., Woloszczuk, W., Hofbauer, L. C., & Pecherstorfer, M. (2005) · PubMed · Cited by 10
Evaluating Bone Mass and Bone Quality in Patients with Breast Cancer
Paterson, A. H. G. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.s.003 · Cited by 10
Integration of denosumab therapy in the management of giant cell tumors of bone
Miles, D. T., Voskuil, R. T., Dale, W. W., Mayerson, J. L., & Scharschmidt, T. J. (2020) · Journal of Orthopaedics · doi:10.1016/j.jor.2020.03.020 · Cited by 9
Hartwich, J. E., Orr, W. S., Ng, C. Y., Spence, Y., McLaughlin, J. M., Furman, W. L., McGregor, L. M., & Davidoff, A. M. (2013) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2012.10.043 · Cited by 9
Douleur et métastases osseuses
Wassermann, J., Lande, B. D. L., Pecking, A. P., & Brasseur, L. (2008) · The French Journal of Urology · doi:10.1016/s1166-7087(08)74574-3 · Cited by 9
Bayer, C., Beckmann, M. W., & Fasching, P. A. (2016) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000333 · Cited by 8
Alraouji, N. N., Hendrayani, S., Ghebeh, H., Almohanna, F., & Aboussekhra, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.013 · Cited by 8
Future Developments in Osteoporosis Therapy
Ng, K. W. (2009) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153009789839192 · Cited by 8
Shimo, T., & Sasaki, A. (2010) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2010.03.001 · Cited by 8
Pathophysiology of myeloma bone disease
Oyajobi, B. O., & Mundy, G. R. (2004) · CRC Press eBooks · doi:10.1201/b13347-9 · Cited by 8
Role of denosumab in breast cancer
Bartsch, R., & Steger, G. G. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903146877 · Cited by 9
RANKL inhibitors: a bright future?
Roux, S. (2005) · Joint Bone Spine · doi:10.1016/j.jbspin.2005.10.015 · Cited by 8
Peng, J., Li, Y., Wang, J., Zhang, F., Liu, K., & Wang, Z. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.02.023 · Cited by 7
RetractedAlraouji, N. N., Çolak, D., Almohanna, F., Alaiya, A. A., & Aboussekhra, A. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02151-8 · Cited by 7
Individualization of Bisphosphonate Therapy
Body, J. (2007) · Springer eBooks · doi:10.1007/978-3-540-28266-2_27 · Cited by 7
Self-citationMiyaji, Y., Kurihara, A., Kamiyama, E., Shiiki, T., Kawai, K., & Okazaki, O. (2009) · Xenobiotica · doi:10.1080/00498250802590745 · Cited by 7
Owen, S., Sanders, A. J., MASON, M. D., & Jiang, W. G. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3339 · Cited by 7
Treatment of tumor-induced hypercalcemia: a solved problem?
Body, J., & Mancini, I. L. (2003) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.3.2.241 · Cited by 7
Self-citationMaldonado-Gonzales, E., & Pietschmann, P. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0812-3 · Cited by 6
Mouse models and the RANKL/OPG axis in myeloma bone disease
Dingli, D., & Russell, S. J. (2007) · Leukemia · doi:10.1038/sj.leu.2404875 · Cited by 6
Gandhi, M., Bakhai, V., Trivedi, J., Mishra, A., de Andrés, F., LLerena, A., Sharma, R., & Nair, S. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101532 · Cited by 6
Colvin, L., & Fallon, M. (2015) · doi:10.1093/med/9780199656097.003.0132 · Cited by 6
Vitamin D and bone-How does vitamin D regulate bone formation and resorption?-
Suda, T. (2004) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.80.407 · Cited by 6
A new role for OPG: Putting RANKL in its place
Ostrowski, M. C. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.206 · Cited by 5
Local delivery of osteoprotegerin may be a way of reinforcing orthodontic anchorage
Li, Y., & Tang, L. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.09.022 · Cited by 5
Inhibition effect of enteropeptidase on RANKL–RANK signalling by cleavage of RANK
Zhao, Y., Jin, M., Ma, J., Zhang, S., Li, W., Chen, Y., Zhou, Y., Hong, T., Liu, Y., Wang, L., et al. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.08.005 · Cited by 5
RANK pathway in cancer: underlying resistance and therapeutic approaches
Tufail, M., & Wu, C. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2129752 · Cited by 5
Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis.
Morris, G. J., & Mitchell, E. (2007) · PubMed Central · Cited by 5
Osteoclast-targeted therapy for metastatic prostate cancer
Lee, R. J., & Smith, M. R. (2008) · Therapy · doi:10.2217/14750708.5.1.63 · Cited by 5
Герштейн, Е. С., Тимофеев, Ю. С., Zuev, A. A., & Кушлинский, Н. Е. (2015) · Advances in molecular oncology · doi:10.17650/2313-805x.2015.2.3.51-59 · Cited by 5
Bisphosphonates et traitements innovants de l’ostéolyse tumorale
Debiais, F. (2008) · Revue du Rhumatisme · doi:10.1016/j.rhum.2008.01.003 · Cited by 5
Jin, M., Chen, Y., Zhao, Y., Che, L., Ma, Y., Li, J., Wang, Y., Tao, H., Ma, J., Pan, B., et al. (2017) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-017-8188-6 · Cited by 4
DIAGNOSIS AND TREATMENT OF MYELOMA BONE DISEASE
Roodman, G. D. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511551901.006 · Cited by 4
Pharmacological mechanisms of therapeutics
Tsourdi, E. A., Ominsky, M. S., Rachner, T. D., Hofbauer, L. C., & Kostenuik, P. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00073-7 · Cited by 4
Breast Cancer: Rank Ligand Inhibition
Bartsch, R., Steger, G. G., Gnant, M., & Ziebermayr, R. (2010) · Breast Care · doi:10.1159/000321122 · Cited by 5
Malignancy-Associated Hypercalcemia and Medical Management
Horwitz, M. J., & Stewart, A. F. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00063-0 · Cited by 4
Advances in the management of myeloma bone disease
Shipman, C. M., Oyajobi, B. O., & Mundy, G. R. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.16.2781 · Cited by 4
Biology and Treatment of Skeletal Manifestations in Multiple Myeloma
Stavropoulos, N., Papadoyiannis, A., Maltezas, D., Stavrou, P. Z., Babis, G., Papagelopoulos, P., Pangalis, G., & Kyrtsonis, M. (2014) · Journal of Cancer Therapy · doi:10.4236/jct.2014.54045 · Cited by 1
(2022) · Biointerface Research in Applied Chemistry · doi:10.33263/briac134.396 · Cited by 4
Der RANK-Ligand-Antikörper Denosumab als Beispiel der biotechnologischen Medikamentenentwicklung
Trubrich, A., Kocijan, R., Muschitz, C., & Resch, H. (2011) · Osteologie/Osteology · doi:10.1055/s-0037-1619994 · Cited by 3
What is the rank of RANKL in spondylarthritis?
Loddenkemper, K., & Burmester, G. R. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23289 · Cited by 3
Cody, J. J., Rivera, Á. A., Lyons, G. R., Yang, S. W., Wang, M., Ashley, J. W., Meleth, S., Feng, X., Siegal, G. P., & Douglas, J. T. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2012.179 · Cited by 3
Andjelkovic, Z., Katić, V., Mihailovic, D., Petrović, A., & Bubanovic, I. (2004) · Archive of oncology · doi:10.2298/aoo0402112a · Cited by 3
Heterologous expression, purification and function of the extracellular domain of human RANK
Wei, Y., Zhan, Y., Chen, P., Liu, Z., Zhang, H., Liu, D., Zhang, J., Yu, M., Mo, W., Zhang, X., et al. (2017) · BMC Biotechnology · doi:10.1186/s12896-017-0405-y · Cited by 3
Thomas, C., & Lamoureux, F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00053-4 · Cited by 3
Enfermedad metastásica ósea: Diagnóstico y tratamiento
Garbayo, A., Villafranca, E., de Blas, A., Tejero, A., Eslava, E., Manterola, A., Romero, P., & Martínez, M. (2004) · Anales del Sistema Sanitario de Navarra · doi:10.4321/s1137-66272004000600014 · Cited by 3
Schwarz, E. M., Keefe, R. J. O., Xing, L., Looney, R. J., & Ritchlin, C. T. (2005) · Current Opinion in Orthopedics · doi:10.1097/01.bco.0000176422.00241.d4 · Cited by 3
Molecular mechanisms of cancer metastases to bone
Chirgwin, J. M., & Guise, T. A. (2003) · Current Opinion in Orthopedics · doi:10.1097/00001433-200310000-00003 · Cited by 3
Immunoregulation of Osteoclast Differentiation in Multiple Myeloma Bone Disease
Grano, M., Brunetti, G., & Colucci, S. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374895-9.00006-2 · Cited by 3
Dougall, W. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374895-9.00032-3 · Cited by 2
Mechanisms of Humoral Hypercalcemia of Malignancy in Leukemia/Lymphoma
Sherry, T., Wessel, P., Katherine, N. E., & Thomas, J. P. (2011) · InTech eBooks · doi:10.5772/24408 · Cited by 2
Osteoprotegerin: A neutralizing receptor, protector of bones and a potential antiresorptive agent
Andjelkovic, Z., Katić, V., Mihajlović, D., Zivkovic, V. D., Petrović, A., & Lalošević, D. (2005) · Medicinski pregled · doi:10.2298/mpns0508362a · Cited by 2
Metadata
- Authors
- Body, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., Nakanishi, A., Holloway, D., Martin, S. W., Dunstan, C. R., & Bekker, P. J.
- Affiliations
- Institut Jules Bordet (BE)
- Mayo Clinic (US)
- Weston Park Cancer Centre (GB)
- Centre Hospitalier Universitaire de Lille (FR)
- Hôpital Saint-Louis (FR)
- Penn State Milton S. Hershey Medical Center (US)
- The Christie Hospital (GB)
- Amgen (United States) (US)
- Corresponding author
- Bekker, Pirow J.
- ORCID
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-01-23
- Volume
- 97
- Issue
- S3
- Pages
- 887-892
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1986310612
- Cited by
- 383
- References
- 18
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 9 · 2018: 8 · 2017: 14 · 2016: 7 · 2015: 12 · 2014: 17 · 2013: 19 · 2012: 17
- FWCI
- 17.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Keywords
- osteoprotegerin, RANKL, RANK, multiple myeloma, breast cancer, bone metastasis, osteolytic lesions, bone resorption, pamidronate, osteoclasts, drug safety, dose escalation, hypercalcemia, congestive heart failure, herpes zoster, phase I
- MeSH terms
- Pamidronate, Antineoplastic Agents, Bone Neoplasms, Bone Resorption, Breast Neoplasms, Diphosphonates, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glycoproteins, Humans, Male, Middle Aged, Multiple Myeloma, Treatment Outcome, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
